Crow Point Partners LLC cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 78.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,048 shares of the medical instruments supplier’s stock after selling 3,820 shares during the quarter. Crow Point Partners LLC’s holdings in Becton, Dickinson and were worth $203,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Guardian Life Insurance Co. of America grew its stake in shares of Becton, Dickinson and by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 6 shares during the period. Family Firm Inc. grew its stake in shares of Becton, Dickinson and by 0.5% during the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after purchasing an additional 6 shares during the period. Northwest Quadrant Wealth Management LLC grew its stake in shares of Becton, Dickinson and by 0.4% during the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after purchasing an additional 6 shares during the period. Wellington Shields & Co. LLC grew its stake in shares of Becton, Dickinson and by 0.3% during the 2nd quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock worth $496,000 after purchasing an additional 7 shares during the period. Finally, Northstar Group Inc. grew its stake in shares of Becton, Dickinson and by 0.3% during the 2nd quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock worth $584,000 after purchasing an additional 9 shares during the period. 86.70% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the transaction, the insider now owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now directly owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock worth $15,242,688 in the last three months. 1.40% of the stock is currently owned by company insiders.

A number of brokerages recently commented on BDX. Wells Fargo & Company reissued a “positive” rating and issued a $235.00 price objective (up from $225.00) on shares of Becton, Dickinson and in a research note on Tuesday, October 24th. They noted that the move was a valuation call. Royal Bank Of Canada reissued a “hold” rating and issued a $210.00 price objective on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a research note on Friday, October 20th. Bank of America Corporation reissued a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $205.14.

Becton, Dickinson and Company (NYSE:BDX) opened at 208.65 on Tuesday. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $214.72. The stock has a market capitalization of $47.48 billion, a price-to-earnings ratio of 60.43 and a beta of 1.05. The firm has a 50-day moving average of $199.98 and a 200-day moving average of $195.13.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s revenue was down 5.1% on a year-over-year basis. During the same quarter last year, the business posted $2.35 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2017/10/31/becton-dickinson-and-company-bdx-stake-decreased-by-crow-point-partners-llc.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.